Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation

Table 4 Univariate and multivariate analysis of risk factors related to tumor recurrence

Risk factors	Univariate analysis			Multivariate analysis
	3-yr recurrence-free survival rate	HR (95%CI)	Log rank P value	Exp(b) (95%CI)	P value
Tumor grading G3-G4 (vs G1-G2)	66.7% vs 74.2%	1.76 (0.289-13.149)	0.4934
Presence of microvascular invasion (vs absence)	60.0% vs 80.7%	2.74 (0.451-39.277)	0.2071
Multiple nodules at pathology (vs single)	69.1% vs 85.7%	2.15 (0.460-9.070)	0.3478
Repeated TACE (vs single)	74.1% vs 80.0%	1.08 (0.244-4.821)	0.9148
Necrosis on CTA ≤ 50% (vs > 50%)	59.3% vs 100.0%	NA1	0.0098	NA1	NA1
MC unfulfilled at pathology (vs fulfilled)	21.4% vs 92.0%	13.84 (10.121-636.416)	< 0.0001	11.6 (1.932-69.646)	0.0077
Absence of DEB-TACE (vs presence)	61.5% vs 87.4%	4.47 (1.005-22.188)	0.0493	15.45 (1.457-163.766)	0.0237
α-fetoprotein > 70 ng/mL (vs ≤ 70 ng/mL)	33.3% vs 90.9%	10.31 (4.749-370.242)	0.0008	15.31 (1.766-132.614)	0.0137

¹Heart rate calculation and the inclusion of the covariate in the multivariate analysis was not applicable due to the lack of hepatocellular carcinoma recurrence events in necrosis on the cumulative tumor area (CTA) > 50% group. TACE: Transcatheter arterial chemoembolization; DEB: Doxorubicin-eluting bead; MC: Milan Criteria; NA: Not available.